

A list of all abbreviations and terms appearing in this issue of *Therapy*.

5DFUR	5-deoxy-5-fluorouridine	COPD	Chronic obstructive pulmonary disease	GSHPx	Glutathione peroxidase
5-FU	5-fluorouracil	COX	Cyclo-oxygenase	GSK3 β	Glycogen synthase kinase 3
AA	Atypical antipsychotic	CSF	Cerebrospinal fluid	GSRs	Gastrointestinal System Rating Scale
AAV	Adeno-associated virus	CSII	Continuous subcutaneous insulin infusion	GSSG-R	Glutathione reductase
ABC	ATP-binding cassette	CT	Computed tomography	HCC	Hepatocellular carcinoma
ACAAI	American College of Allergy, Asthma and Immunology	CTF	C-terminal fragment	Hcy	Homocysteine
ACH	Acetyl choline	CU	Chronic urticaria	HES	Hypereosinophilic syndrome
AchEI	Acetylcholinesterase inhibitors	CVID	Common variable immunodeficiency	HFS	Hand-foot syndrome
ACS	Acute coronary syndrome	DAS	Disability Assessment for Dementia	HOMA-B	Homeostasis model assessment
AD	Alzheimer's disease	DFCR	5-deoxy-5-fluorocytidine	HR	Hazard ratio
ADAS	Alzheimer's disease assessment scale	DFS	Disease-free survival	HTA	Health Technology Assessment
ADCS	Alzheimer's Disease Cooperative Study	DHFU	Dihydrofluorouracil	IAP	Inhibitors of apoptosis
ADHD	Attention-deficit hyperactivity disorder	DLP	Dose-length product	IBS	Irritable bowel syndrome
ADL	Activities of Daily Living inventory	DMSO	Dimethyl sulfoxide	ICAD	International Conference on Alzheimer's disease
ADR	Acute dystonic reaction	DO	Detrusor overactivity	ICAS	Inner City Asthma Study
AGO	Argonaute proteins	DOE	Department of Energy's	IDO	Idiopathic detrusor overactivity
AGO2	Argonaute-2	DPD	Dihydropyrimidine dehydrogenase	IFN	Interferon
AMD	Age-related macular degeneration	DPP-4	Dipeptidyl peptidase-4	Ig	Immunoglobulin
AML	Acute myeloid leukemia	DSD	Detrusor external sphincter dyssynergia	IGF-1	Insulin-like growth factor
Apo	Apolipoprotein	DSM	Diagnostic and Statistical Manual of Mental Disorders	IGF1-R	IGF-1 receptor
ATP	Adenosine 5'-triphosphate	dsRNA	Double-stranded RNA	IIQ-7	Incontinence Impact Questionnaire 7-item short form
AUA	American Urological Association	DTI	Direct thrombin inhibitor	IOAB	Idiopathic overactive bladder
AUC	Area under the curve	DVT	Deep venous thrombosis	IP-10	Interferon- γ -inducible protein-10
AUS	Artificial urinary sphincter	Dx/HA	Dextranomer/hyaluronic acid	IR	Insulin receptor
AVANT	AVastin AdjuvaNt Trial	EAU	European Association of Urology	IRS	Insulin receptor substrates
A β	Amyloid β	EE	Eosinophilic esophagitis	ISD	Intrinsic sphincter deficiency
BBB	Blood-brain barrier	EGDs	Esophagogastroduodenoscopies	ISG	IFN-stimulated gene
BICC-C	Bolus, Infusional or Capecitabine with Camptosar-Celecoxib Trial	EGFR	EGF receptor	LABA	Long-acting β -agonist
BMI	Body mass index	EMEA	European Medicines Agency	LDL-C	Low-density lipoprotein cholesterol levels
BNP	B-type natriuretic peptide	EOAD	Early-onset Alzheimer's disease	LEAD	Liraglutide Effect and Action in Diabetes
BTX	Botulinum toxin	Exp5	Exportin-5	LIF	Leukemia inhibitory factor
BTX-A	Botulinum toxin serotype A	ECM	Extracellular matrices	LIS	Insulin lispro
CAIRO	Capecitabine, Irinotecan, Oxaliplatin trial	FdUDP	Fluorodeoxyuridine diphosphate	LOAD	Late-onset Alzheimer's disease
CAPIRI	Capecitabine/Irinotecan	FdUMP	Fluorodeoxyuridine monophosphate	LTP	Lipid transfer protein
CATIE	Clinical Antipsychotic Trials of Intervention Effectiveness	FdUTP	Fluorodeoxyuridine triphosphate	LV	Leucovorin
CCTA	Cardiac computed tomography angiography	FIT	Fellows-in-training	M	End of the meal
CDA	Cytidine deaminase	FOCUS2	FU, Oxaliplatin, CPT-11: Use and Sequencing trial - 2	MAP	Mitogen activated protein
CDR-sb	Clinical Dementia Rating sum of boxes	FOLFIRI	5-FU and irinotecan	MAPT	Microtubule associating protein tau
CES1	Carboxylesterase-1	FOLFOX	5-FU and oxaliplatin	MCI	Mild cognitive impairment
CFU	Colony-forming units	FTLD	Frontotemporal lobar degeneration	MCP-1	Monocyte chemoattractant protein-1
CGRP	Calcitonin gene-related peptide	FUDP	Fluorouridine diphosphate	MDR	Multidrug resistance
CHO	Chinese Hamster Ovary	FUdR	5-fluoro-2-deoxycytidine	MIP	Macrophage inflammatory protein
CI	Confidence interval	FUMP	Fluorouridine monophosphate	miRNA	MicroRNA
CIC	Clean intermittent catheterization	FUTP	Fluorouridine triphosphate	MMC	Myelo meningocele
CLASP	Cholesterol Lowering Agent to Slow Progression	GAG	Glycosaminoglycan	MMSE	Mini Mental State Examination
CML	Chronic myelogenous leukemia	GERD	Gastroesophageal reflux disease	MOSAIC	Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer
CMS	Centers for Medicare & Medicaid Services	GI	Gastrointestinal	MRC	Medical Research Council
COAST	Childhood Origins of Asthma study	GIP	Glucosedependent insulinotropic polypeptide	MTC	Methyl thioninium chloride
cog	Cognitive subscale	GIR	Glucose infusion rates	MTD	Maximum tolerated dose
		GLP-1	Glucagon-like peptide-1	n.s	Not significant
		GLU	Insulin glulisine	NBSD	Neurogenic bladder sphincter detrusor dyssynergia
		GRA	Global response assessment	NDO	Neurogenic detrusor overactivity

NFT	Neurofibrillary tangle	PKR	dsRNA-dependent protein kinase	TAR	Trans-activating region
NHS	National Health Service	PLGA	Polylactic-coglycolic acid	TD	Tardive dyskinesia
NMS	Neuroleptic malignant syndrome	PRIDE	Program to Reduce Incontinence by Diet and Exercise trial	tHcy	Total homocysteine
NNOAB	Non-neurogenic overactive bladder	PS	Presenilin	TIMECHF	Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure
Noct	Nocturnal	PTFE	Polytetrafluoroethylene	TK	Thymidine kinase
NPH	Neutral protamine hagedorn	PVR	Post-void residual	TKI	Tyrosine kinase inhibitor
NPSA	National Patient Safety Agency	QoL	Quality-of-life	TLR	Toll-like receptor
NSABP	National Surgical Adjuvant Breast and Bowel Project	QUASAR	Quick and Simple and Reliable trial	TMP	Trimethoprim
NSCLC	Non-small-cell lung cancer	RHI	Regular human insulin	TP	Thymidine phosphorylase
OAB	Overactive bladder	RISC	RNA-induced silencing complex	TRBP	Trans-activating region dsRNA-binding protein
OAD	Oral antidiabetic drug	RNAi	RNA interference	TREE-1	Three Regimens of Eloxatin Evaluation trial
OAS1	2'-5'-oligoadenylate synthetase-1	RNP	Ribonucleotide protein complex;	TS	Thymidylate synthase
OPRT	Orotate phosphoribosyl transferase	ROS	Reactive oxygen species	TTP	Time to-progression
OS	Overall survival	RPN2	Ribophorin II	UDI-6	Urogenital Distress Inventory 6-item short form
P	RNA-polymerase III promoter	RR	Ribonucleotide reductase	UK	Uridine kinase
P	Phosphorylated	RSV	Respiratory syncytial virus	UP	Uridine phosphorylase
PACCE	Panitumumab Advanced Colorectal Cancer Evaluation Study	RVG	Rabies virus glycoprotein	UTI	Urinary tract infection
PACT	Protein activator of interferon-induced protein kinase PKR	SAP	Serum amyloid P component	UTR	Untranslated region
PACT	Patient Preference in Adjuvant Colorectal Therapy	SBP	Systolic blood pressure	VaD	Vascular dementia
PAI-1	Plasminogen activator inhibitor 1	scAAV	Self-complementary adeno-associated viral vector	VKA	Vitamin K antagonist
PAZ	PIWI-Argonaute-Zwille/Pinhead	SCI	Spinal cord injury	VTE	Venous thromboembolism
PBMCs	Primary blood mononuclear cells	SCNT	Somatic cell nuclear transfer	X-ACT	Xeloda in Adjuvant Colon Cancer Therapy trial
PD	Parkinson's disease	shRNA	Short hairpin RNA	ZDF	Zucker diabetic fatty
PDC	Plasmacytoid dendritic cells	siRNA	Short interfering RNA		
PFS	Progression-free survival	SIS	Small intestine submucosa		
PK/PD	Pharmacokinetic/pharmacodynamic	SLIT	Sublingual immunotherapy		
PKB	Protein kinase B	SMX	Sulfamethoxazole		
		SNS	Sacral nerve stimulation		
		SP	Substance P		
		T5	RNA-polymerase III termination signal		
		TAC	Total antioxidant capacity		